It helps to start with what is actually known, rather than what gets repeated: the question of talking to your psychiatrist about ketamine looks straightforward until you try to answer it with real numbers. This guide sets out what is actually established, what varies between providers, and what to establish before committing to anything, written as continuous explanation rather than a checklist, because the reasoning is what transfers to your own situation.
In the United States the same rule applies: a clinic that agrees to treat anyone who asks, without reference to what has already been tried, has replaced clinical judgement with a booking system. Anyone comparing the United States programmes will find this decisive: the subanaesthetic dose used in this work is a fraction of the surgical dose, which is why the person stays awake, breathing independently and able to communicate. Asking for an annualised cost rather than a per-session figure produces a far more useful number and occasionally a revealing pause. Continuous monitoring of blood pressure, heart rate and oxygen saturation is the baseline, because subanaesthetic dosing reliably produces a modest rise in the first two. That is as true in the United States as anywhere else in the country. For anyone weighing options in the United States, the practical difference is that esketamine is approved and more often insurable but less flexible, while intravenous ketamine is off-label, usually self-funded and more adjustable.
Before comparing anything specific to the United States, the underlying clinical picture is worth stating properly. Cost is the constraint that decides the matter for a large share of people, and the numbers are rarely posted plainly. A single intravenous infusion in the United States commonly falls somewhere between four hundred and eight hundred dollars, which puts a six-session induction in the range of roughly two and a half to five thousand dollars before any maintenance. Commercial insurance seldom reimburses off-label intravenous administration, though the associated psychiatric evaluation is sometimes billable. Esketamine is a different story, since an approved indication makes coverage plausible, subject to prior authorisation and documented failure of prior treatments. Before committing to anything, it is worth asking for the total cost of the induction course, the cost of a maintenance session, whether the consultation is billed separately, and what happens financially if treatment is stopped partway through.
How the pieces fit together in practice
Asking whether integration support is included, who provides it and whether it costs extra separates two quite different models of care within a single phone call. Nothing about the United States changes that. A clinic willing to escalate frequency on request, or to supply product without meaningful assessment, has removed the safeguards that keep the risk manageable. It is worth carrying that into every conversation with a the United States provider. Advertising routinely blurs the line between approved esketamine and off-label generic ketamine, and the distinction carries real consequences for coverage. The relevant question about a provider is not only whether they are licensed but whether their training covers both the psychiatric assessment and the physiological monitoring. It is the first thing to establish about any the United States programme. Researchers describe the result as a window of heightened neuroplasticity, which is a hypothesis with support rather than a settled account.
The evidence base deserves an honest summary rather than either dismissal or enthusiasm. Multiple randomised controlled trials have found rapid reductions in depressive symptom scores following single and repeated subanaesthetic ketamine infusions, with effects often visible within hours to days rather than weeks, and a separate line of research has examined rapid reduction of suicidal ideation specifically. Those are real findings from real trials. The significant limitations are equally real: many studies are small, blinding is notoriously difficult because the dissociative effect is obvious to participants, follow-up periods are usually short, and the question of what happens over years of maintenance has not been answered. A reasonable reading is that this is a promising and genuinely useful option for a specific population, not a settled standard of care for everyone.
What varies between providers and why it matters
The short version is that anyone searching for treatment in the United States meets the same wall of interchangeable clinic websites, all promising personalised care and none explaining what that means operationally. Knowing in advance that the dissociative period is temporary, expected and monitored tends to make it considerably less frightening than encountering it unprepared. Patients researching the United States providers run into this constantly. In 2023 the FDA warned publicly about compounded ketamine used at home without monitoring, citing sedation, dissociation and airway risk with no clinician present. That holds in the United States as it does everywhere: a driver is mandatory, and across six sessions in three weeks that means arranging somebody else's time repeatedly rather than once. Resuscitation equipment on site and a clinician credentialed to manage sedation are the structural elements that make the treatment defensible outside a research setting. The the United States listings on this page are organised so that this is checkable rather than assumed. Randomised controlled trials have reported rapid reductions in depressive symptom scores after subanaesthetic infusions, often visible within hours to days rather than the weeks conventional antidepressants require.
The mechanism is where ketamine departs from the antidepressants most people have already tried. Conventional selective serotonin reuptake inhibitors work primarily on monoamine systems and typically need four to six weeks before any effect is assessable. Ketamine acts on the glutamate system, principally as an antagonist at the N-methyl-D-aspartate receptor, and the downstream cascade it appears to trigger involves a surge in brain-derived neurotrophic factor and a measurable increase in synaptic connections in regions associated with mood regulation. Researchers describe this as a window of heightened neuroplasticity. The clinically useful framing is that ketamine may open a period during which the brain is more amenable to change, which is precisely why the therapeutic work done around the infusion matters as much as the infusion.
Why this question is harder than it should be
Read against the the United States market, esketamine, sold as Spravato, holds FDA approval for treatment-resistant depression in adults alongside an oral antidepressant, which puts it in a different regulatory category from generic infusions. The useful test for a remote programme is which components happen remotely and which require a monitored setting, and whether the answer is clear. Where the evidence is strongest concerns short courses in adults who have not responded to at least two adequate antidepressant trials. Solid food is usually restricted for several hours beforehand, largely to limit nausea during administration. Stated without hedging, what people looking at the United States providers usually want is the operational detail, and that is precisely what clinic marketing tends to omit.
The background that makes the United States listings interpretable is this. A standard induction course in most American clinics runs to six sessions delivered over two to three weeks, though the number is a convention inherited from early trial protocols rather than a figure settled by comparative research. Some people are offered four; some programmes run to eight. What happens after induction is the genuinely unresolved part of the field. Response, where it occurs, is often not permanent, and many patients move onto a maintenance schedule of a single session every two to six weeks. Any clinic that presents six infusions as a complete and finished course without discussing what maintenance might look like, and what it might cost over a year, is describing half the treatment.
Safety, screening and the limits of the evidence
The phrase treatment-resistant carries a specific meaning, and it only applies after documented trials at appropriate doses and durations. Applied to the United States, the point is this: the gap between anaesthetic and psychiatric dosing is large enough that describing them as the same treatment obscures more than it explains. Ketamine work sits between psychiatric assessment and sedation management, and clinicians arrive at it from either side with correspondingly different instincts. For anyone whose decision turns on cost, asking whether a provider offers esketamine as well as intravenous administration is among the higher-value questions available.
What follows applies to the United States and to every other market, and it is the part worth reading slowly. Side effects during a session are common, usually transient, and worth knowing about in advance rather than discovering in the chair. Dissociation is the one people ask about most: a sense of distance from the body, altered perception of time, sometimes visual distortion. For most people it peaks partway through the infusion and resolves within twenty to thirty minutes of the drip finishing. Nausea is frequent enough that many clinics give an antiemetic pre-emptively. Blood pressure and heart rate typically rise modestly during administration, which is the reason continuous monitoring is standard and the reason uncontrolled hypertension is treated as a serious caution. Headache, dizziness and a period of grogginess afterwards are ordinary. Driving is prohibited for the rest of the day without exception.
What to do next
Applied to the United States, the point is this: headache, dizziness and several hours of grogginess afterwards are ordinary, and driving is prohibited for the remainder of the day without exception. Whether a programme titrates the dose according to response and tolerability, or runs a fixed protocol for everyone, is a meaningful difference in how individualised the care actually is. That holds in the United States as it does everywhere: the logistics of an induction course are what quietly determine whether people finish treatment or abandon it partway through. Read against the the United States market, whether a programme is led by someone trained in sedation or someone trained in mood disorders changes what gets emphasised and what gets assumed. Pairing sessions with structured psychological support follows directly from the mechanism, which makes its absence a substantive gap rather than a stylistic one. The trial protocols that produced the evidence base were run in monitored medical environments, and the monitoring was part of what made them safe rather than an accessory to it. The the United States listings on this page are organised so that this is checkable rather than assumed.
None of the the United States detail on this page makes sense without the clinical context behind it. Screening is where a careful programme distinguishes itself, and it happens before anyone discusses scheduling. A thorough intake covers cardiovascular history, because of the blood pressure response; personal and family history of psychosis or bipolar disorder, because of the risk of precipitating an episode; hepatic function, because the liver metabolises the drug; substance use history; current medications and their interactions; and pregnancy status. It should also establish what has already been tried and at what dose, since the term treatment-resistant carries a specific meaning that only applies after adequate trials of at least two antidepressants. A consultation that skips most of this and moves quickly to a package price is telling you something about how the clinic is run.
Putting this to use
For anyone weighing options in the United States, the trial evidence is real and also limited: studies tend to be small, follow-up periods short, and blinding is notoriously difficult when the dissociative effect is obvious to participants. Screening should cover cardiovascular history, personal and family history of psychosis or bipolar disorder, hepatic function, substance use history and current medications. It is worth carrying that into every conversation with a the United States provider. A programme should be able to say plainly who is in the building during a session, what their credential is, and what the plan is if a person becomes acutely distressed. Patients researching the United States providers run into this constantly. Response, where it occurs, is frequently not permanent, and many people move onto maintenance sessions spaced every two to six weeks. Travel time belongs in the treatment plan rather than being treated as a detail to solve later. It is the first thing to establish about any the United States programme.
Treatment decisions of this kind belong to a person and the clinician who knows their history. What a directory can usefully do is make sure nobody walks into that discussion missing something they needed.
This page is general information, not medical advice, and no directory can assess whether a treatment is appropriate for an individual. Ketamine is a controlled substance with genuine risks, and its use for mood disorders is off-label apart from esketamine, which holds FDA approval for treatment-resistant depression under a restricted programme. Decisions about treatment should be made with a qualified clinician who knows your full history. If you are in crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988 in the United States, or go to your nearest emergency department.